Cytrx Corp (NASDAQ:CYTR)

CAPS Rating: 2 out of 5

A biopharmaceutical research and development company engaged in developing human therapeutic products based primarily upon its small molecule molecular chaperone co-induction technology.

Recs

0
Player Avatar Buhlzi (< 20) Submitted: 4/18/2007 9:10:39 AM : Outperform Start Price: $27.61 CYTR Score: -82.77

Nice accumulation and uptrend

Featured Broker Partners


Advertisement